COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,220 Articles (22,733 medRxiv, 8,487 bioRxiv)

Most recent first Previous |  Page 1935: Articles 19341-19350  | Next

SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma
Andreano, E., Piccini, G., Licastro, D., Casalino, L., Johnson, N. V., Paciello, I., Dal Monego, S., Pantano, E., Manganaro, N., Manenti, A., Manna, R., Casa, E., Hyseni, I., Benincasa, L., Montomoli, E., Amaro, R. E., McLellan, J. S., Rappuoli, R.
10.1101/2020.12.28.424451 — Posted: 2020-12-28 Discussion: Onsite
Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection
Winkler, E. S., Gilchuk, P., Yu, J., Bailey, A. L., Chen, R. E., Zost, S. J., Jang, H., Huang, Y., Allen, J. D., Case, J. B., Sutton, R. E., Carnahan, R. H., Darling, T. L., Boon, A. C. M., Mack, M., Head, R. D., Ross, T. M., Crowe, J. E., Diamond, M.
10.1101/2020.12.28.424554 — Posted: 2020-12-28
Losartan promotes cell survival following SARS-CoV-2 infection in vitro
Nejat, R., Sadr, A. S., Freitas, B. T., Crabtree, J., Pegan, S. D., Tripp, R. A., Najafi, D. J.
10.1101/2020.12.27.424507 — Posted: 2020-12-28
Emerging SARS-CoV-2 diversity revealed by rapid whole genome sequence typing.
Moustafa, A. M., Planet, P.
10.1101/2020.12.28.424582 — Posted: 2020-12-28
MHC-II constrains the natural neutralizing antibody response to the SARS-CoV-2 spike RBM in humans
Castro, A., Ozturk, K., Zanetti, M., Carter, H.
10.1101/2020.12.26.424449 — Posted: 2020-12-28
Can age-distribution be an indicator of the goodness of COVID-19 testing?
Hoseinpour Dehkordi, A., Nemati, R., Tavousi, P.
10.1101/2020.12.21.20248690 — Posted: 2020-12-28
Maori and Pacific People in New Zealand have higher risk of hospitalisation for COVID-19
Steyn, N., Binny, R. N., Hannah, K., Hendy, S., James, A., Lustig, A., Ridings, K., Plank, M. J., Sporle, A.
10.1101/2020.12.25.20248427 — Posted: 2020-12-28 Discussion: Onsite
The neutralization effect of Montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies
Durdagi, S., Avsar, T., Orhan, M. D., Serhatli, M., Balcioglu, B. K., Ozturk, H. U., Kayabolen, A., Cetin, Y., Aydinlik, S., Bagci-Onder, T., Tekin, S., Demirci, H., Guzel, M., Akdemir, A., Calis, S., Oktay, L., Tolu, I., Butun, Y. E., Erdemoglu, E., Olkan, A., Tokay, N., Isik, S., Ozcan, A., Acar, E., Buyukkilic, S., Yumak, Y.
10.1101/2020.12.26.424423 — Posted: 2020-12-27
The mechanism of SARS-CoV-2 nucleocapsid protein recognition by the human 14-3-3 proteins
Tugaeva, K. V., Hawkins, D. E. D. P., Smith, J. L. R., Bayfield, O. W., Ker, D.-S., Sysoev, A. A., Klychnikov, O. I., Antson, A. A., Sluchanko, N. N.
10.1101/2020.12.26.424450 — Posted: 2020-12-27
SARS-CoV-2 mutations among minks show reduced lethality and infectivity to humans
Konishi, T.
10.1101/2020.12.23.424267 — Posted: 2020-12-27

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).